Douglas Earl Martin
SEC CIK 1362155 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | SVP, GC | 488.3K | — | $114.2K | 7 | 2023-08-14 | 2026-08-21 |
Most active insiders at ALLO, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Chang David D | Pres, CEO, Dir | — | $289.5K |
| 2 | Roberts Zachary | EVP of R, D | — | $104.2K |
| 3 | Douglas Earl Martin | SVP, GC | — | $103.3K |
| 4 | Parker Geoffrey M. | CFO | — | $88.5K |
| 5 | Beneski Benjamin Machinas | SVP, Chief Technical Off | — | $51.7K |
| 6 | Yoshiyama Annie | SVP, Fin | — | $29.3K |
| 7 | Kazam Joshua A | Dir | — | — |
Transactions 7
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-25 16:43 | 2026-08-21 | ALLO | Allogene Therapeutics, Inc. | Douglas Earl Martin | SVP, GC | S - Sale | $2.12 | -29.7K | 488.3K | -6% | -$63.0K | |
| D | 2026-02-04 | 2026-02-02 | ALLO | Allogene Therapeutics, Inc. | Douglas Earl Martin | SVP, GC | S - Sale | $1.76 | -22.9K | 564.9K | -4% | -$40.3K |
| 2025-02-05 | 2025-02-03 | ALLO | Allogene Therapeutics, Inc. | Douglas Earl Martin | SVP, GC | S - Sale | $1.71 | -6,404 | 587.8K | -1% | -$11.0K | |
| D | 2025-01-28 | 2025-01-24 | ALLO | Allogene Therapeutics, Inc. | Douglas Earl Martin | SVP, GC | A - Grant | $0.00 | +144.9K | 594.3K | +32% | $0 |
| 2024-08-23 | 2024-08-21 | ALLO | Allogene Therapeutics, Inc. | Douglas Earl Martin | SVP, GC | F - Tax | $2.79 | -28.3K | 449.3K | -6% | -$79.0K | |
| D | 2024-01-31 | 2024-01-25 | ALLO | Allogene Therapeutics, Inc. | Douglas Earl Martin | SVP, GC | A - Grant | $0.00 | +41.8K | 477.6K | +10% | $0 |
| DM | 2023-08-17 | 2023-08-14 | ALLO | Allogene Therapeutics, Inc. | Douglas Earl Martin | GC | A - Grant | $0.00 | +435.8K | 109.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations